Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

@article{Manson2013MenopausalHT,
  title={Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.},
  author={Joann E. Manson and Rowan Chlebowski and Marcia L. Stefanick and Aaron Aragaki and Jacques E. Rossouw and Ross L. Prentice and Garnet L. Anderson and Barbara V Howard and Cynthia A Thomson and Andrea Z LaCroix and Jean Wactawski-Wende and Rebecca D. Jackson and Marian C. Limacher and Karen L. Margolis and Sylvia Wassertheil-Smoller and Shirley A. A. Beresford and Jane A. Cauley and Charles B. Eaton and Margery Gass and Judith Hsia and Karen C Johnson and Charles Kooperberg and Lewis H. Kuller and Cora E. Lewis and Simin Liu and Lisa W. Martin and Judith K. Ockene and Michael O'Sullivan and Lynda H. Powell and Michael S Simon and Linda Van Horn and Mara Z. Vitolins and Robert B. Wallace},
  journal={JAMA},
  year={2013},
  volume={310 13},
  pages={1353-68}
}
IMPORTANCE Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention. OBJECTIVE To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up. DESIGN, SETTING, AND PARTICIPANTS A total of 27,347 postmenopausal women aged 50 to 79 years were enrolled at 40 US centers. INTERVENTIONS Women with an intact uterus… CONTINUE READING
Highly Influential
This paper has highly influenced 26 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 43 times over the past 90 days. VIEW TWEETS